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Abstract
Background
The study aimed to assess the feasibility of conducting large scale HIV prevention clinical tri-
als in Mozambique by measuring HIV prevalence and incidence among women of reproduc-
tive age. This paper describes the baseline socio-demographic characteristics of the
Mozambique Microbicides Development Programme (MDP) feasibility cohort, baseline
prevalence of HIV and other STIs, and HIV incidence.
Methods
The Mozambique MDP feasibility study was conducted from September 2007 to August
2009 in urban Mavalane and rural Manhic¸a, in Southern Mozambique. Sexually active, HIV
negative women aged 18 years and above were recruited to attend the study clinic every 4
weeks for a total of 40 weeks. At baseline, we collected demographic and sexual behaviour
data, samples to test for sexually transmitted infections (STI) and conducted HIV rapid test-
ing. STI and HIV testing were repeated at clinical follow-up visits. We describe HIV preva-
lence of women at screening, the demographic, behavioural and clinical characteristics of
women at enrolment, and HIV incidence during follow-up.
Results
We screened 793 women (369 at Mavalane and 424 at Manhic¸a) and enrolled 505 eligible
women (254 at Mavalane and 251 at Manhic¸a). Overall HIV prevalence at screening was
17%; 10% at Mavalane and 22% at Manhic¸a. Women screened at Manhic¸a were twice as
likely as women screened at Mavalane to be HIV positive and HIV positive status was
associated with younger age (18–34), lower educational level, not using a reliable method of
contraception and being Zionist compared to other Christian religions. At enrolment con-
traceptive use was low in both clinics at 19% in Mavalane and 21% in Manhic¸a, as was
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reported condom use at last sex act at 48% in Mavalane and 25% in Manhic¸a. At enrolment,
8% of women tested positive for Trichomonas vaginalis, 2% for Neisseria gonorrhoeae, 4%
for Chlamydia trachomatis and 46% for bacterial vaginosis. In Manhic¸a, 8% of women had
active syphilis at screening. HIV incidence was 4.3 per 100 person years at Mavalane and
9.2 per 100 person years at Manhic¸a.
Conclusions
We demonstrated the ability to recruit a cohort of women at risk of HIV who were willing to
participate in clinical research. The high HIV incidence necessitates additional action around
HIV prevention for women and offers opportunities to evaluate the impact of available pre-
vention options, such as treatment as prevention and oral PrEP. The high HIV incidence
and STI prevalence also offers opportunities to evaluate the added benefit of potential pre-
vention options such as new formulations of oral PrEP, vaginal microbicides (also called top-
ical PrEP), vaccines, and multi-purpose technologies for HIV, STIs and contraception.
Introduction
With approximately 1.5 million adults living with HIV in 2015 and an adult HIV prevalence of
10.5%, Mozambique is among the top ten countries with the highest HIV prevalence in the
world [1,2]. HIV prevalence is even higher for women of reproductive age at 13%, peaking
among women aged 25 to 29 at 17% [3]. Women’s HIV prevalence differs dramatically across
the 11 provinces, from 3% in the northern province of Niassa to 30% in the southern province
of Gaza [3]. HIV prevalence is higher among urban than rural women at 18% versus 11% [3].
In the areas of interest for this study, Maputo City and Manhic¸a District, HIV prevalence for
women is 21% and 16% respectively [3].
In Mozambique, there is limited data on HIV incidence. Based on UNAIDS estimates there
were 100,000 new HIV infections in the country in 2013 [4]. Mozambique still accounted for
8% of all new HIV infections in Sub-Saharan Africa, despite recent reports of a 27% decline in
new HIV infections from 2005 to 2013 [1,4]. Low and inconsistent condom use, multiple part-
ners, transactional sex, low rates of male circumcision, and mobility and migration are consid-
ered the main drivers of the epidemic in Mozambique [5].
The Mozambican Government has made efforts to address the HIV epidemic and is com-
mitted to the UNAIDS Fast-Track Strategy to end its AIDS epidemic by 2030 [6]. However,
despite the expansion of HIV testing and treatment services, less than half of all adults in need
of antiretroviral therapy received it in 2012 [1]. This proportion drops to less than a quarter of
adults when applying the new World Health Organisation 2013 guidelines to initiate treatment
when an individuals’ CD4 count falls below 500 cells/μL or immediately for more vulnerable
individual’s [1]. Expanded efforts in both HIV prevention and treatment are urgently required
to address the HIV epidemic in Mozambique.
Since 2004, the Mozambican Government has supported the principal of new HIV biomed-
ical prevention research and initiatives to establish local research sites for microbicide clinical
trials. As a result, a Mozambican partnership between the National Institute for Health (INS),
the Manhic¸a Health Research Centre (CISM) and the Foundation for Community Develop-
ment (FDC) joined the Microbicides Development Programme (MDP) [7,8]. This partnership
hosted the Mozambique MDP feasibility study in the Mavalane area of Maputo City and
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Manhic¸a District, in southern Mozambique. The study aimed to assess the feasibility of con-
ducting large scale biomedical HIV prevention clinical trials in Mozambique by measuring
HIV prevalence and incidence. This paper describes the baseline socio-demographic and beha-
vioural characteristics of the Mozambique MDP feasibility cohort, baseline prevalence of HIV
and other sexually transmitted infections (STIs), and HIV incidence.
Methods
The Mozambique MDP feasibility study was conducted from September 2007 to August 2009.
The study recruited at two dedicated research clinics located within the grounds of National
Health Service (NHS) facilities, at 1 de Junho Health Centre in the peri-urban Mavalane area
of Maputo City and at Manhic¸a Health Centre in the rural Manhic¸a District which is approxi-
mately 80km north of Maputo City. The study aimed to recruit approximately 500 women
across both centres with 40 weeks of follow-up. The sample size was based on the precision of
the estimate of HIV incidence per 100 women years; a 5% incidence of HIV and 350 women
years at risk (approx. 500 women) gives a one-sided confidence interval width of 2.39.
Information about the study was disseminated at community mobilisation meetings, via
local stakeholders, and at the NHS clinic facilities. Women were invited to attend the research
clinics to find out more about the study and to be screened for eligibility. At the initial visit,
women who provided informed consent were screened against the following eligibility criteria:
18 years of age or above, HIV negative, not pregnant, sexually active in the last month, willing
and able to give informed consent, and willing to undergo regular urine pregnancy tests, HIV
testing, and speculum examinations. Demographic and baseline behaviour data were collected,
HIV counselling was provided, HIV rapid tests were performed, and blood samples were col-
lected for syphilis testing. Data on the use of any family planning method were collected and
for the purposes of this analysis we defined ‘reliable contraceptives’ as the oral contraceptive
pill, injectable Depot medroxyprogesterone acetate (DMPA), the intrauterine contraceptive
device (IUCD), and female sterilisation. Eligible women were invited to attend an enrolment
visit within 6 weeks.
At enrolment, a genital examination was conducted during which endocervical samples
were collected for Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT), and a high
vaginal swab for Trichomonas vaginalis (TV) and Bacterial vaginosis (BV). Women with symp-
toms and clinical signs of STIs were managed according to Mozambican syndromic manage-
ment guidelines and all diagnosed STIs were treated [9]. Women who tested HIV positive at
screening or during follow up were referred to clinical care which included the provision of
anti-retroviral therapy.
Participants were asked to attend the study clinic every 4 weeks for a total of 40 weeks. Par-
ticipants who missed a scheduled follow-up visit were contacted either by phone or at the loca-
tion address they provided, up to three times by the tracking team. HIV rapid tests and genital
examinations were conducted at clinic visits 12, 24 and 40 weeks after enrolment, with STI
tests repeated at week 24. HIV status was assessed using the MDP parallel dual rapid test algo-
rithm performed by study nurses (Abbott Determine HIV1/ 2 test and Trinity Biotech Uni-
Gold). The MDP contracted reference laboratory in South Africa (Contract Laboratory Ser-
vices (CLS), the School of Pathology, University of the Witwatersrand, Johannesburg) con-
firmed all HIV sero-converters using the standard MDP algorithm which involved two
different Enzyme Immunoassays (EIA) and a confirmatory positive HIV qualitative DNA
PCR, P24 EIA or HIV-1 Western Blot [10]. Syphilis serology was done by rapid plasma reagin
(RPR) (Omega Diagnostics) and TPHA; active syphilis was defined by positivity in both tests.
NG and CT was evaluated through polymerase chain reaction (PCR), and TV was evaluated
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using In-Pouch [11]. BV samples were collected using the Dacron swab, the slides were Gram
stained and BV was diagnosed using the Ison Hay method [12]. HIV and STI samples were
placed in the respective transport medium and transported to the respective laboratories
under temperature-controlled conditions, and from there onwards to CLS in batches as
required. Syphilis and TV tests were conducted at the laboratory of the 1 de Junho Health Cen-
tre and the CISM laboratory for Mavalane and Manhic¸a respectively, and NG and CT tests
were conducted at CLS. At enrolment, clinic staff failed to collect samples for TV, NG/CT and
BV from 10%, 7%, and 2% of participants, and this increased at the week 24 visit to 22%, 15%
and 16% who attended the visit, respectively.
Data were double entered into a common SQL database at each site. Demographic and
behavioural characteristics were tabulated to consider differences by HIV status at screening.
Differences between HIV negative and positive women were examined by calculating chi-
square tests and fitting logistic regression models. Differences that attained statistical signifi-
cance at the 10% level using a likelihood ratio test (LRT) were considered for the multivariate
model. We considered differences to be statistically significant based on a 95% confidence
interval. Demographic, behavioural and clinical characteristics of women at enrolment were
tabulated. T-tests were used to compare means. STI point prevalence at weeks 0 and 24 (num-
ber with positive result/total number tested) and HIV incidence (number of new HIV+ diagno-
ses/women years at risk) were calculated. We estimated the time of HIV seroconversion as the
midpoint between the last negative and first positive HIV tests. Data were analyzed using Stata
14 (StataCorp, College Station, Texas, USA).
Approval was obtained from the Mozambique National Ethics Committee (CNBS)
(approval number 16/CNBS/07). Written informed consent, supported by a comprehension
test, was obtained from all participants. Participants were not given a remittance for the study
visits, but were offered transport in Manhic¸a or reimbursed the cost of public transport in
Mavalane, and offered food and drink during the study visits at both sites.
Results
Women screened
Seven-hundred and ninety-three (793) women attended a screening visit, 369 (47%) at Mava-
lane and 424 (53%) at Manhic¸a. One-hundred and sixty-three (163) women (21%) were ineli-
gible, 132 (17%) who were HIV positive, 23 (3%) who had a positive pregnancy test at
screening or enrolment, and 8 (1%) who were not sexually active or unlikely to comply with
the protocol (Fig 1). Another 125 (16%) were identified as eligible but did not return for
enrolment. A total of 505 eligible women enrolled in the study giving a screening to enrol-
ment ratio of 1.57.
HIV prevalence of women at screening and associated socio-
demographic characteristics
HIV prevalence at screening differed substantially between the sites, at 10% (37/369) at Mava-
lane and 22% (95/424) at Manhic¸a. As shown in Table 1, a higher proportion of HIV positive
women were aged between 18 to 34 years old, had not completed primary education, were
Zionist, not using reliable contraception and had not used a condom at last sex. These variables
were all associated with HIV status at screening. The majority of women were unemployed
and this did not differ by HIV status. Similarly the majority of women reported being in long-
term stable relationships (97%) and this did not differ by HIV status (p-value 0.790).
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The numbers of HIV positive women within each site allowed only descriptive statistics
(Table 1). However it is noteworthy that women screened at Manhic¸a were older than women
screened at Mavalane with a mean age of 32.1 compared to 25.6 (ttest, p-value<0.001) and
that a higher proportion of women in Manhic¸a were Zionist. In addition, a higher proportion
of HIV negative women in Mavalane had higher levels of education and reported condom use
at last sex than HIV negative women in Manhic¸a. A higher proportion of HIV positive women
in Manhic¸a were not using reliable contraception compared to positive women in Mavalane.
In a multivariate model, women screened at Manhic¸a were twice as likely as women
screened at Mavalane to be HIV positive when controlling for age, education, religion and
Fig 1. Consort diagram.
https://doi.org/10.1371/journal.pone.0173243.g001
High HIV prevalence and incidence among women in Southern Mozambique
PLOS ONE | https://doi.org/10.1371/journal.pone.0173243 March 28, 2017 5 / 13
contraceptive use (Table 2). Women aged 25 to 34 compared to 18 to 24 year olds, women
who had not completed primary education compared to those who had, women who reported
being Zionist compared to other Christian belief systems, and women who reported not using
a reliable contraceptive method compared to those who did, were more likely to be HIV-posi-
tive (Table 2). Condom use at last sex act was not significantly associated with HIV status in
the multivariate models (LRTest p = 0.096).
Socio-demographic and sexual behaviour characteristics of women
enrolled
Of the 793 women screened, 505 (64%) were eligible and consented to enrol in the study; 254
(50%) at Mavalane and 251 (50%) at Manhic¸a (Table 3). The mean age of women recruited
Table 1. HIV status at screening by selected demographic and sexual behavioural characteristics.
Mozambique cohort p-value Mavalane—Urban Manhic¸a—Rural
All HIV- HIV + HIV - HIV + HIV - HIV +
N screened, n (%) 793 (100) 661 (83) 132 (17) 332 (90) 37 (10) 329 (78) 95 (22)
Clinic
•Mavalane 369 (47) 332 (50) 37 (28) <0.001
•Manhic¸a 424 (53) 329 (50) 95 (72)
Age
•18–241 358 (46) 311 (47) 47 (36) 0.010 224 (68) 20 (56) 87 (27) 27 (29)
•25–34 220 (28) 168 (26) 52 (40) 56 (17) 11 (31) 112 (35) 41 (44)
•35–44 124 (16) 106 (16) 18 (14) 26 (8) 2 (6) 80 (25) 16 (17)
•45+ 83 (10) 70 (11) 13 (10) 25 (8) 3 (8) 45 (14) 10 (11)
Missing 8 6 2 1 1 5 1
Mean age (SD) ttest 29.0 (10.1) 29.0 (10.3) 29.4 (9.0) 0.657 25.4 (8.9) 27.0 (8.6) 32.6 (10.4) 30.3 (9.0)
Education
•Did not complete primary 329 (42) 254 (38) 75 (57) <0.001 68 (20) 18 (49) 186 (57) 57 (60)
•Completed primary or further 462 (58) 406 (62) 56 (43) 264 (80) 19 (51) 142 (43) 37 (40)
Missing 2 1 1 0 0 1 1
Employment status
•Employed (full or part time) 162 (20) 141 (21) 21 (16) 0.167 52 (16) 7 (19) 89 (27) 14 (15)
•Unemployed 629 (80) 519 (79) 110 (84) 280 (84) 30 (81) 239 (73) 80 (85)
Missing 2 1 1 0 0 1 1
Religion
•Christian 636 (80) 540 (82) 96 (73) <0.001 284 (86) 29 (79) 256 (79) 67 (71)
•Zionist 101 (13) 71 (11) 30 (23) 23 (7) 6 (16) 48 (15) 24 (26)
•Other 51 (7) 46 (7) 5 (4) 25 (8) 2 (5) 21 (6) 3 (3)
Missing 5 4 1 0 0 4 1
Reliable contraceptive
•Any2 181 (23) 162 (25) 19 (14) 0.011 89 (27) 9 (24) 73 (22) 10 (11)
•None 612 (77) 499 (75) 113 (86) 243 (73) 28 (76) 256 (78) 85 (89)
Condom use at last sex act
•No 530 (67) 428 (65) 102 (77) 0.005 180 (54) 29 (78) 248 (75) 73 (77)
•Yes 263 (33) 233 (35) 30 (23) 152 (46) 8 (22) 81 (25) 22 (23)
1 Age was calculated from the screening visit at which point one woman was 17 years of age, but was enrolled one day after her 18th birthday.
2 Of 181 women, 117 reported oral hormonal contraceptive, 54 reported DMPA, 10 reported other reliable methods which were tubal ligation and the
intrauterine contraceptive device.
https://doi.org/10.1371/journal.pone.0173243.t001
High HIV prevalence and incidence among women in Southern Mozambique
PLOS ONE | https://doi.org/10.1371/journal.pone.0173243 March 28, 2017 6 / 13
into the cohort was 29.3 years (SD 10.2 years; range 17–59). Women in Mavalane were on
average 6.6 years younger than women in Manhic¸a. A higher proportion of women enrolled in
Mavalane than in Manhic¸a completed primary education or were unemployed. More women
in Manhic¸a reported their religion as Zionist, while more women in Mavalane reported
belonging to other Christian belief systems, compared to the other site. The dominant lan-
guage was Portuguese in Mavalane and Changana in Manhic¸a (the main local dialect of South-
ern Mozambique). The majority of women in Mavalane lived in a household headed by a
parent, with a higher proportion of women enrolled in Manhic¸a than in Mavalane living in
households headed by their partner or themselves. Most women lived in households with two
people sleeping per room, although a higher proportion of women in Manhic¸a lived in house-
holds were four people slept per room compared to Mavalane.
The use of reliable contraceptives at enrolment was low in both clinics at 19% in Mavalane
and 21% in Manhic¸a, with no significant difference between the clinics (Table 3). The main
methods of contraception were the oral pill (Mavalane 15%, Manhica 13%) and the depot
medroxyprogesterone acetate (DMPA) injectable (Mavalane 2%, Manhic¸a 7%). Women
reported low levels of sexual activity in the week before enrolment (median 1, IQR 0–1, range
0–5) and only 6 women reported having a casual rather than a long-term partner. Forty-eight
percent of women enrolled in Mavalane and 25% in Manhic¸a reported using a condom at
their last sex act, and the difference between the clinics reached statistical significance
(p>0.001). Eighty-eight percent of women (443) reported being aged 15 to 19 years old the
first time they had sex, with only 5% (25) younger and 7% (35) older (no data for 2 women).
At enrolment, 8% of women tested positive for TV, 2% for NG, 4% for CT and 46% for BV
(Table 4). There were no statistically significant differences between the sites. In Manhic¸a, 8%
(21/250) of women had active syphilis, although results are not available at Mavalane.
Table 2. Multivariate model assessing characteristics of HIV positive women at screening.
HIV- HIV + LRT
p-value
AOR
(95% CI)
p-value
N screened, n (%) 661 (83) 132 (17)
Clinic
•Mavalane 332 (50) 37 (28) <0.001 1.00 0.002
•Manhic¸a 329 (50) 95 (72) 2.05 (1.29, 3.27)
Age
•18–24 311 (47) 47 (36) <0.001 1.00 0.004
•25–34 168 (26) 52 (40) 1.35 (0.82, 2.22)
•35–44 106 (16) 18 (14) 0.49 (0.25, 0.96)
•45 70 (11 13 (10) 0.51 (0.24, 1.07)
Education
•Completed primary of further 406 (62) 56 (43) 0.001 1.00 0.004
•Did not complete primary 254 (38) 75 (57) 2.00 (1.25, 3.18)
Religion
•Christian 540 (82) 96 (73) 0.034 1.00 0.036
•Zionist 71 (11) 30 (23) 1.83 (1.09, 3.08)
•Other 46 (7) 5 (4) 0.62 (0.23, 1.62)
Reliable contraceptive
•Any 162 (25) 19 (14) 0.001 1.00 0.003
•None 499 (75) 113 (86) 2.33 (1.33, 4.17)
https://doi.org/10.1371/journal.pone.0173243.t002
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Table 3. Demographic characteristics at enrolment.
Mavalane Manhic¸a p-value
N enrolled, n (%) 254 (50) 251 (50)
Age <0.001
•18–24 169 (67) 58 (23)
•25–34 37 (15) 91 (37)
•35–44 23 (9) 67 (27)
•45+ 24 (9) 31 (13)
Missing 1 4
Mean (SD) ttest 26.0 (9.57) 32.6 (9.70) <0.001
Education <0.001
•Did not complete primary 51 (20) 145 (58)
•Completed primary of further 203 (80) 106 (42)
Employment status <0.001
•Employed (full/part-time) 36 (14) 69 (27)
•Unemployed 218 (86) 182 (73)
Religion 0.041
•Christian 219 (86) 9)
•Zionist 19 (8) 36 (15)
•Other 16 (6) 15 (6)
Missing 3
Language <0.001
•Changana 93 (37) 1)
•Portuguese 146 (58) 39 (16)
•Other 14 (5) 7 (3)
Missing 1 3
Head of household <0.001
•Partner 75 (30) 5)
•Self 10 (4) 47 (19)
•Parent or other family 169 (67) 65 (26)
Number of people per room <0.001
•4 or more people per room 31 (12) 59 (24)
•3 people per room 72 (28) 68 (27)
•2 people per room 140 (55) 101 (40)
•1 person per room 11 (4) 23 (9)
Reliable contraceptive 0.533
•Any* 48 (19) 53 (21)
•None 206 (81) 198 (79)
*23 Depot medroxyprogesterone acetate (DMPA), 72 oral pills, 5 Intrauterine Device and 1 female sterilization.
https://doi.org/10.1371/journal.pone.0173243.t003
Table 4. STIs at baseline.
N, (%) Total Mavalane Manhic¸a
TV 37/456 (8) 13/213 (6) 24/243 (10)
NG 10/470 (2) 7/227 (3) 3/243 (1)
CT 18/470 (4) 7/227 (3) 11/243 (5)
BV (I&H 3 = positive) 226/494 (46) 117/249 (47) 109/245 (44)
Syphilis1 - - - - 21/250 (8)
1Result from screening visit
https://doi.org/10.1371/journal.pone.0173243.t004
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Women in Mavalane lived in households with indicators of higher socio-economic status
than women in Manhic¸a (Table 5), as indicated by a higher proportion of Mavalane house-
holds having electricity, running water, a radio, television, refrigerator, computer, bicycle, car
and even mosquito net.
Follow up data on sexual behaviour, STI prevalence and HIV incidence
In total, 360 (71%) women completed follow-up (38 weeks) and as shown in Fig 1 this was
similar in both clinics (72% in Mavalane and 71% in Manhic¸a). The median weeks of follow
up were week 40 (interquartile range IQR 24, 40) in Mavalane, and week 40 (IQR 32, 40) in
Manhic¸a. However, only 50% of women in Mavalane (127/254) and 56% (141/251) of women
in Manhic¸a attended 75% (3/4) of the scheduled clinical follow-up visits.
During follow-up, few women reported concurrent multiple partners (n = 4), having sex
during menstruation (n = 11), intravaginal cleansing or insertion (n = 24), or anal sex (n = 15).
Although 324 women (173 in Manhic¸a and 151 in Mavalane), attended the week 24 visit,
STI test results were not available for almost 20% of them. Based on this limited data, TV prev-
alence was 7% (18/253), NG prevalence was 3% (7/274) and CT prevalence was 1% (4/270).
Of the 505 women enrolled, follow-up HIV tests were available for 452 (90%) women (234
in Mavalane and 251 in Manhic¸a). There were 21 new HIV infections in 315 person years of
follow up with an overall incidence of 6.66 per 100 person years (95% CI: 4.34, 10.22). There
were 7 infections at Mavalane in 163 person years of follow up with a HIV incidence of 4.29
per 100 person years (95% CI: (2.04, 8.99) and 14 at Manhic¸a in 152 person years of follow up
with a HIV incidence of 9.21 per 100 person years (95% CI: 5.46, 15.55).
Discussion
In this paper we have presented the baseline characteristics of the Mozambique MDP feasibil-
ity study, which was the first such study in Mozambique. We demonstrated the ability to
recruit a population of women at risk of HIV who were willing to participate in clinical
research. A subsequent study was conducted in the Sofala province of northern Mozambique
which showed high levels of willingness to participate in HIV prevention trials among women
[13].
In this study the screening to enrolment ratio was favourable when compared to the other
MDP feasibility studies (with 33% ineligibility) and the MDP301 phase III clinical trial (with
30% ineligibility) conducted in South Africa, Tanzania, Uganda and Zambia [7,8,14]. The pro-
portion of eligible women who did not return for enrolment was similar to the other MDP
Table 5. Socio-economic characteristics at enrolment: Proportion of women who reported household ownership of assets.
Mavalane Manhic¸a p-value
N enrolled, n (%) 254 (50) 251 (50)
Household electricity 225 (89) 105 (42) <0.001
Household water tap 166 (65) 74 (29) <0.001
Radio 214 (84) 137 (55) <0.001
Television 225 (89) 98 (39) <0.001
Refrigerator 178 (70) 78 (31) <0.001
Computer 46 (18) 9 (4) <0.001
Bicycle 37 (15) 56 (22) 0.025
Car 59 (23) 35 (14) 0.007
Mosquito net 162 (64) 129 (51) 0.005
https://doi.org/10.1371/journal.pone.0173243.t005
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feasibility studies (approximately 18%), but higher than in the MDP 301 clinical trial when
women were offered a vaginal product to use (7%) [7]. It is encouraging that the rate of eligibil-
ity in Mozambique was not lower than in the other feasibility studies [7]. In Mozambique, eli-
gible women who chose not to return for enrolment were not tracked as this was considered
an active refusal to consent. It is not surprising that the return rates were similar across the
other MDP feasibility studies which were also not interventional, yet lower compared to inter-
ventional clinical trials where the motivation to participate is likely to be higher.
Rates of study ineligible are mainly driven by HIV prevalence at screening. Baseline HIV
prevalence in Mavalane was lower than at other MDP centres. However HIV prevalence in
Manhic¸a was comparable to the HIV prevalence reported in the MDP feasibility studies and
clinical trial in Johannesburg in South Africa (19–20%) and Mwanza in Tanzania (20–25%),
but lower than in Mazabuka in Zambia (29–30%), Durban in South Africa (36–47%) and the
Africa Centre in South Africa (28–50%) [7,8,14].
In Mavalane, the HIV prevalence observed among women in the MDP feasibility study
(10%) was lower than expected based on the national surveillance estimate of 21% in Maputo
City [3]. In Manhic¸a, although the HIV prevalence (22%) was higher than the provincial aver-
age (16% in 2009), it was similar to that reported in the same district in HIV testing centres
(23% in 2004–5) and ante-natal clinics (29% in 2010), although lower than among women in a
cross-sectional survey (43% in 2012) [3,15,16]. The lower than anticipated HIV prevalence at
screening may indicate that the recruitment messages were successful in terms of only attract-
ing women who thought they were HIV negative, although we did not collect data on HIV
testing history.
As expected, HIV prevalence peaked among women below 34 years old, consistent with
other studies [3,17,18]. We found an association between lower education and higher HIV
prevalence as seen in some studies [17,18] but not observed in the national surveillance pro-
gramme [3]. We found that women who reported using a reliable contraceptive method were
less likely to be HIV positive at screening than women not using a reliable method, which is
similar to other data in Mozambique which has either observed no difference or an association
in the same direction [17,18]. In our study we saw a higher risk of HIV prevalence among
women who reported being Zionist although there is no data to compare this with in
Mozambique.
Condom use at last sex act was low, especially in Manhic¸a. However, the national survey
reported only 8% of women used a condom at last sex act in 2009 although the rate was higher
at 44% among unmarried women [3]. Few of the other cohort studies in Mozambique have
reported on condom use at last sex, but have reported condom use as the main contraceptive
method used by between 8% to 21% of women [13,17,18]. The highest reported use has been
among 15 to 24 year old women in a national survey conducted in 2001 (71%) [19]. It is note-
worthy that in our study, reported condom use at last sex act was not associated with HIV
infection which is indicative of the limitations of using condom use at last sex as a measure of
consistent use.
Longitudinal HIV incidence data is limited in Mozambique with approximately five
reported studies across the country [13,17,20–22]. Incidence data among women has been
reported in post-partum clinics at 2.9 per 100 person-years in Maputo Province and at 3.6 in
Gaza Province, at 4.6 in a cohort study in Gaza, at 4.9 from cross-sectional surveys in Manhic¸a,
at 6.5 in a cohort study in Sofala, and as high as 14.1 based on consecutive prevalence surveys
in Manhic¸a [13,17,20–22]. Participants were similar across the studies, as sexually active
women of reproductive age, although with the exception of the latter referenced study in Man-
hic¸a, women in the other studies tended to be slightly younger than in our study with mean
ages below the mid-20s, more comparable to the Mavalane than the Manhic¸a cohort. The
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overall HIV incidence reported in this study (6.7 per 100 person years) was at the upper end of
incidence estimates, and the incidence reported in Manhic¸a at 9.2 per 100 person years is con-
sistent with the higher rates in this province which are thought to be stabilising [22].
The weighted estimate of HIV incidence in the MDP feasibility studies in South Africa,
Tanzania, Uganda and Zambia was 6.2 per 100 woman years ranging from 3.5 to 12.6 [7]. The
overall HIV incidence in the MDP 301 clinical trial was 4.6 per 100 woman years ranging from
1.5 to 6.1 [8]. The HIV incidence observed in Mozambique demonstrates that both Mavalane
and Manhic¸a are feasible sites for the conduct of large scale HIV prevention clinical trials.
There is also limited data on STI prevalence in Mozambique. In this study, NG was lower,
CT was higher, and TV and syphilis was similar to that reported in the other MDP 301 trial
sites among HIV negative women (NG 3%, CT 8%, TV 9%, syphilis 4%) [8]. Our findings are
also comparable to those reported in a 2004 survey in the Tete province for NG (2.5%) and CT
(4.1%) although higher for syphilis (5%) [23]. However, the prevalence of STIs in our study are
substantially lower than in a 2000 survey among women enrolled predominantly at ante-natal
clinics, as well as family planning clinics and in the community in Manhic¸a (NG 14%, CT 8%,
TV 31%, syphilis 12%) [24]. The reasons for the very high prevalence observed in the 2000 sur-
vey are not clear, although 12% of the sample was HIV positive and there was a non-significant
trend for the presence of all STIs in HIV positive women.
This was the first study to evaluate the feasibility of conducting a clinical trial of vaginal
microbicides in Mozambique. The findings demonstrate that both centres were able to recruit
and follow-up women with high HIV incidence in a non-interventional cohort study. In
Mavalane, the HIV prevalence was lower than at the other MDP research centres while the
HIV incidence was comparable. Whereas in Manhic¸a, the HIV prevalence was similar to the
other MDP research centres while the HIV incidence was much higher. These criteria make
conducting large-scale biomedical HIV prevention trials in these communities highly feasible.
The main limitation of this study was that the retention rates were not sufficient for a phase
III clinical trial, although we expect retention could be improved with the offer of an investiga-
tional product as we observed in the other MDP centres. Another limitation of the study was
the sub-optimal collection of STI samples as per the protocol schedule. Our ability to measure
STI prevalence during follow-up was hindered by both poor retention and inefficient follow
up for specimen collection, both of which could be improved in future studies. A further limi-
tation was that we did not collect marital status, involvement in transactional or commercial
sex, parity, or alcohol or substance use. Marital status and involvement in transactional sex
have been shown to be associated with HIV infection in Mozambique [3,18].
Both HIV prevalence and incidence remain unacceptably high in these two areas of
Mozambique but especially in the Manhic¸a area which is located on the transport route from
Maputo to Beira. There is an urgent need to expand both ART treatment and prevention
options for people in Mozambique, including the provision of oral pre-exposure prophylaxis
[25]. In parallel there is continued need for community mobilisation around HIV testing, pre-
vention and treatment, STI prevention and treatment, and reliable family planning options. In
the meantime we need additional data on HIV and STI prevalence and incidence in other
provinces of Mozambique and continued monitoring nationally to understand the epidemics
and the potential impact of any new prevention modalities. Our findings support the feasibility
of conducting HIV prevention trials in Mozambique and enrolling a cohort of women at par-
ticularly high risk of HIV acquisition. The high HIV incidence necessitates additional action
around HIV prevention and offers opportunities to evaluate the impact of available prevention
options such as treatment as prevention and oral PrEP. The high HIV incidence and STI prev-
alence also offers opportunities to evaluate the added benefit of potential prevention options
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such as new formulations of oral PrEP, vaginal microbicides (also called topical PrEP), HIV
vaccines, and multi-purpose technologies for HIV, STIs and contraception.
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